Subsys Makes A Bad Impression On FDA REMS Panel Members

CMS and FDA data showed prescriptions jumping while other fentanyl products were coming down.

FDA’s advisory committee review of the transmucosal immediate release fentanyl (TIRF) risk evaluation and mitigation strategy was a mixed bag of observations, recommendations, and opinions, but one thing was clear: Subsys made a bad impression on the panel.

The TIRF REMS has been viewed as a model of how other class-wide or shared REMS could work. The tone...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet